Notably, women show an improved glycemic control, a greater peripheral and hepatic insulin sensitivity and a reduced HPG with respect to men (36–38), likely a consequence of a sex-dimorphic regulation of glucose homeostasis (39), to which the hepatic signaling of sexual hormones strongly contributes (40, 41), thus leading to a different susceptibility to NAFLD between the two sexes. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.